CTLA-4 blockade: therapeutic potential in cancer treatments

Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor immune responses and leading to durable anti-tum...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tarhini, Ahmad A, Iqbal, Fatima
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2010
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2895779/
https://ncbi.nlm.nih.gov/pubmed/20616954
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller